每周皮下注射司美格鲁肽对比每日利拉鲁肽对无糖尿病超重或肥胖成人休重的影响:STEP 8 随机临床试验
STEP 8 是一项在美国 19 个中心开展的 68 周随机开放标签 3b 期试验,纳入 338 例无糖尿病的超重或肥胖成人。结果显示,每周皮下注射司美格鲁肽 2.4 mg 组第 68 周体重平均变化 -15.8%,优于每日利拉鲁肽 3.0 mg 组的 -6.4%(差值 -9.4 个百分点,95%CI -12.0 至 -6.8,P<.001)。
要点
- 司美格鲁肽 2.4 mg 每周一次组体重平均下降 15.8%,利拉鲁肽 3.0 mg 每日一次组下降 6.4%。
- 司美格鲁肽组体重下降≥10%、≥15%、≥20% 的比例分别为 70.9%、55.6%、38.5%,均高于利拉鲁肽组。
- 司美格鲁肽组因任何原因停药比例为 13.5%,利拉鲁肽组为 27.6%。
核心结论
- 在无糖尿病的超重或肥胖成人中,每周皮下注射司美格鲁肽对比每日皮下注射利拉鲁肽(均联合饮食和体力活动咨询),第 68 周体重下降显著更大。
研究设计与样本
- 随机、开放标签、68 周、3b 期试验,在美国 19 个中心开展,2019 年 9 月至 2021 年 5 月进行。
- 纳入体重指数≥30 或≥27 且伴有至少 1 种体重相关合并症、无糖尿病的成人,共 338 例。
- 参与者按 3:1:3:1 随机分配至每周皮下注射司美格鲁肽 2.4 mg(16 周递增;n=126)、匹配安慰剂、每日皮下注射利拉鲁肽 3.0 mg(4 周递增;n=127)或匹配安慰剂,均联合饮食和体力活动;安慰剂组合并(n=85)。
- 不能耐受司美格鲁肽 2.4 mg 者可接受 1.7 mg;不能耐受利拉鲁肽 3.0 mg 者停药并可重新开始 4 周滴定。
- 主要终点为第 68 周体重百分比变化,确证性次要终点为体重下降≥10%、≥15%、≥20% 的达成情况。
主要发现
- 第 68 周体重较基线平均变化:司美格鲁肽组 -15.8% vs 利拉鲁肽组 -6.4%(差值 -9.4 个百分点,95%CI -12.0 至 -6.8;P<.001);合并安慰剂组体重变化为 -1.9%。
- 体重下降≥10% 的比例:司美格鲁肽组 70.9% vs 利拉鲁肽组 25.6%(比值比 6.3,95%CI 3.5 至 11.2;P<.001)。
- 体重下降≥15% 的比例:司美格鲁肽组 55.6% vs 利拉鲁肽组 12.0%(比值比 7.9,95%CI 4.1 至 15.4;P<.001)。
- 体重下降≥20% 的比例:司美格鲁肽组 38.5% vs 利拉鲁肽组 6.0%(比值比 8.2,95%CI 3.5 至 19.1;P<.001)。
- 因任何原因停药的比例:司美格鲁肽组 13.5%,利拉鲁肽组 27.6%;胃肠道不良事件报告率:司美格鲁肽组 84.1%,利拉鲁肽组 82.7%。
关键数值与推荐
- 主要终点第 68 周体重百分比变化:司美格鲁肽组 -15.8% vs 利拉鲁肽组 -6.4%,差值 -9.4 个百分点(95%CI -12.0 至 -6.8),P<.001。
- 体重下降≥10%:司美格鲁肽组 70.9% vs 利拉鲁肽组 25.6%,比值比 6.3(95%CI 3.5 至 11.2),P<.001。
- 体重下降≥15%:司美格鲁肽组 55.6% vs 利拉鲁肽组 12.0%,比值比 7.9(95%CI 4.1 至 15.4),P<.001。
- 体重下降≥20%:司美格鲁肽组 38.5% vs 利拉鲁肽组 6.0%,比值比 8.2(95%CI 3.5 至 19.1),P<.001。
- 因任何原因停药比例:司美格鲁肽组 13.5% vs 利拉鲁肽组 27.6%;胃肠道不良事件:司美格鲁肽组 84.1% vs 利拉鲁肽组 82.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Phase 3 trials have not compared semaglutide and liraglutide, glucagon-like peptide-1 analogues available for weight management. OBJECTIVE: To compare the efficacy and adverse event profiles of once-weekly subcutaneous semaglutide, 2.4 mg, vs once-daily subcutaneous liraglutide, 3.0 mg (both with diet and physical activity), in people with overweight or obesity. DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, 68-week, phase 3b trial conducted at 19 US sites from September 2019 (enrollment: September 11-November 26) to May 2021 (end of follow-up: May 11) in adults with body mass index of 30 or greater or 27 or greater with 1 or more weight-related comorbidities, without diabetes (N = 338). INTERVENTIONS: Participants were randomized (3:1:3:1) to receive once-weekly subcutaneous semaglutide, 2.4 mg (16-week escalation; n = 126), or matching placebo, or once-daily subcutaneous liraglutide, 3.0 mg (4-week escalation; n = 127), or matching placebo, plus diet and physical activity. Participants unable to tolerate 2.4 mg of semaglutide could receive 1.7 mg; participants unable to tolerate 3.0 mg of liraglutide discontinued treatment and could restart the 4-week titration. Placebo groups were pooled (n = 85). MAIN OUTCOMES AND MEASURES: The primary end point was percentage change in body weight, and confirmatory secondary end points were achievement of 10% or more, 15% or more, and 20% or more weight loss, assessed for semaglutide vs liraglutide at week 68. Semaglutide vs liraglutide comparisons were open-label, with active treatment groups double-blinded against matched placebo groups. Comparisons of active treatments vs pooled placebo were supportive secondary end points. RESULTS: Of 338 randomized participants (mean [SD] age, 49 [13] years; 265 women [78.4%]; mean [SD] body weight, 104.5 [23.8] kg; mean [SD] body mass index, 37.5 [6.8]), 319 (94.4%) completed the trial, and 271 (80.2%) completed treatment. The mean weight change from baseline was -15.8% with semaglutide vs -6.4% with liraglutide (difference, -9.4 percentage points [95% CI, -12.0 to -6.8]; P < .001); weight change with pooled placebo was -1.9%. Participants had significantly greater odds of achieving 10% or more, 15% or more, and 20% or more weight loss with semaglutide vs liraglutide (70.9% of participants vs 25.6% [odds ratio, 6.3 {95% CI, 3.5 to 11.2}], 55.6% vs 12.0% [odds ratio, 7.9 {95% CI, 4.1 to 15.4}], and 38.5% vs 6.0% [odds ratio, 8.2 {95% CI, 3.5 to 19.1}], respectively; all P < .001). Proportions of participants discontinuing treatment for any reason were 13.5% with semaglutide and 27.6% with liraglutide. Gastrointestinal adverse events were reported by 84.1% with semaglutide and 82.7% with liraglutide. CONCLUSIONS AND RELEVANCE: Among adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide compared with once-daily subcutaneous liraglutide, added to counseling for diet and physical activity, resulted in significantly greater weight loss at 68 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04074161.
引用
- Rubino DM, Greenway FL, Khalid U, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022. PMID: 35015037. doi:10.1001/jama.2021.23619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。